Therapy Areas: Oncology
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
2 May 2025 - Blue Earth Therapeutics, a UK-based developer of radiopharmaceutical therapies, on Thursday reported further progress in the development of its radio-hybrid, lutetium-labelled, PSMA targe...
TransCode Therapeutics reports progress in metastatic cancer trial
2 May 2025 - RNA oncology company TransCode Therapeutics Inc (NASDAQ:RNAZ) on Thursday reported further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.TTX-MC13...
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
1 May 2025 - Ingenium Therapeutics, a South Korea-based clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, announced on Wednesday that it has received positi...
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management
1 May 2025 -

At the 2025 Community Oncology Alliance Annual Meeting, group purchasing organisation AllyGPO and specialty distributor BioCareSD sh...

Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
30 April 2025 - Nuformix plc (LSE: NFX), a pharmaceutical development company focused on unmet needs in fibrosis and oncology, confirmed on Wednesday that the European Medicines Agency's Committe...
Atossa Therapeutics secures new US patent for proprietary (Z)-endoxifen formulations
30 April 2025 - Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq:ATOS) announced on Wednesday that it has been granted US Patent No. 12,281,056, expanding protection for its (Z...